Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 12—December 2013

Research

Guillain-Barré Syndrome Surveillance during National Influenza Vaccination Campaign, New York, USA, 2009

Gregory P. Giambrone1Comments to Author , Shelley M. Zansky, Millicent Eidson, Pamela G. Duncan, Louise-Anne McNutt, and Guthrie S. Birkhead
Author affiliations: New York State Department of Health, Albany, New York, USA (G.P. Giambrone, S.M. Zansky, M. Eidson, P.G. Duncan, G.S. Birkhead); University at Albany School of Public Health, Rensselaer, New York, USA (L.-A. McNutt, G.S. Birkhead)

Main Article

Table 3

Vaccination status of patients with confirmed or probable GBS, New York State Department of Health GBS surveillance system, 2009–2010*-

Reporting source Total confirmed/probable GBS case-patientss A(H1N1)pdm09 monovalent vaccine status
Received, no. (%) Did not receive, no. (%)
Clinical Network† and SPARCS‡ 140 19 (14) 121 (86)
SPARCS 130 19 (15) 111 (85)
Clinical Network 91 13 (14) 78 (86)
SPARCS-only¶ 49 6 (12) 43 (88)

*GBS, Guillain-Barré syndrome; SPARCS, Statewide Planning and Research Cooperative System.
†Network of >2,494 reporting clinical neurologists.
‡SPARCS refers to all suspected cases identified through hospital discharge data (some of these cases might have been identified by the Clinical Network as well).
¶Cases missed by the Clinical Network and identified only through SPARCS.

Main Article

1Current affiliation: Weill Cornell Medical College, New York, New York, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO